Advances of small molecule targeting of kinases

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Reversible protein phosphorylation is a fundamental cellular process regulated by protein kinases.
• Dysregulation of protein kinases is implicated in numerous human diseases, particularly cancer.
• Despite numerous approvals, current protein kinase inhibitors (PKIs) target a limited number of kinases and cancer types.

Purpose of the Study:

• To review recent advances in the development of protein kinase inhibitors (PKIs).
• To discuss the challenges hindering the expansion of PKI-based therapies.
• To explore alternative strategies for targeting protein kinases in disease.

Main Methods:

• Literature review of recent scientific publications on protein kinase inhibitors.
• Analysis of FDA-approved PKIs and their targeted kinases.
• Discussion of current challenges and emerging therapeutic strategies.

Main Results:

• Over 500 protein kinases exist in the human genome, yet only 22 are targeted by approved PKIs.
• Current FDA-approved PKIs are effective against only 14 of over 100 cancer types.
• Significant potential exists for developing novel PKIs to address unmet medical needs.

Conclusions:

• The limited targeting scope of current PKIs highlights a substantial opportunity for innovation.
• Overcoming challenges in PKI development is essential for expanding cancer treatment options.
• Exploring new strategies is crucial for harnessing the full therapeutic potential of targeting protein kinases.